Core Insights - Korro Bio, Inc. has initiated dosing in its REWRITE study for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD) [1][2] - The REWRITE study aims to evaluate the safety and tolerability of KRRO-110 in up to 64 participants, with interim data expected in the second half of 2025 [2][7] - KRRO-110 is designed to restore therapeutic M-AAT protein levels by utilizing the body's endogenous ADAR enzyme, with a focus on both lung and liver manifestations of AATD [2][5] Company Overview - Korro is a clinical-stage biopharmaceutical company focused on developing genetic medicines using its proprietary RNA editing platform, OPERA™ [6][8] - The company is transitioning from a research organization to a clinical-stage drug development entity, with plans to advance three product candidates into the clinic by 2027 [4][6] - Korro's approach aims to enhance the precision and tunability of genetic medicines by editing RNA instead of DNA, potentially improving long-term tolerability [6][8] Product Development - KRRO-110 is the first product candidate from Korro's RNA editing platform, targeting the genetic disorder AATD caused by a mutation in the SERPINA1 gene [5][7] - The REWRITE study consists of two parts: single and multiple dose-escalating studies, with secondary endpoints focusing on pharmacokinetic and pharmacodynamic parameters [2][4] - The company is also advancing additional pipeline programs, including a partnership with Novo Nordisk in a cardiometabolic indication [3][4]
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update